Immune Thrombocytopenic Purpura – Current Treatment – Detailed, Expanded Analysis – Treatment Algorithms – Claims Data Analysis (US)
Immune thrombocytopenia purpura (ITP) is an autoimmune form of acquired thrombocytopenia that leads to a decrease in platelet production and an increased risk of bleeding. Current therapies for ITP can be broadly divided into immunomodulators and thrombopoietin receptor agonists (TPO–RAs). Systemic glucocorticoids and TPO–RAs are the cornerstones of clinical management; however, biologics such as Roche's Rituxan (rituximab, biosimilars) provide additional options for refractory patients. In 2018, two novel therapies for chronic ITP—Rigel Pharmaceuticals’ Tavalisse, an oral Syk inhibitor, and Dova Pharmaceuticals’ Doptelet (avatrombopag), a second-generation TPO–RA—launched in the United States. With the treatment landscape continuing to evolve, this report offers insights from real-world claims data into prescribing trends in ITP to help new players better understand current treatment practices in ITP that may help define the market niche for their emerging product.
What patient shares do key therapies and brands garner by line of therapy in newly diagnosed ITP patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed ITP patients?
How have systemic steroids and TPO–RAs been integrated into the treatment algorithm, and what are their sources of business?
What percentage of ITP patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
What percentage of ITP patients are treated with monotherapy versus combination therapy? What are the most commonly used combinations?
What are the product-level compliance and persistency rates among drug-treated patients?
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
Markets covered: United States
Key companies: Novartis, Amgen, Dova Pharmaceuticals, Rigel Pharmaceuticals
Immune Thrombocytopenic Purpura - Current Treatment - Detailed, Expanded Analysis - Treatment Algorithms - Claims Data Analysis (US)
Treatment algorithms CDA immune thrombocytopenic purpura US May 2022
Treatment Algorithms CDA immune thrombocytopenic purpura US 2022 Dashboard
Vidhi Khosla, M.Sc., is an analyst on the Infectious, Niche, and Rare Diseases team at Clarivate. She has several years of experience providing consulting, research, and analytic support in the pharmaceutical and healthcare domain and has worked in numerous therapy areas, including neurology, women’s health, metabolic disorders, and rare diseases. Prior to joining Clarivate, Ms. Khosla worked at WNS Global Services and DelveInsight Business Research LLP. She earned her bachelor’s and master’s (gold medalist) degrees in biochemistry from Delhi University and Kurukshetra University, respectively.